FDA approves Lupin's generic liraglutide injection, database record shows

The FDA has approved a generic liraglutide injection made by Lupin Pharmaceuticals, according to the agency's drug approval database. The record for application ANDA215421 shows the application was approved on July 22, 2025, under standard review rather than priority review ^[1].

What the approval covers

Lupin's product is a generic of Victoza, the brand-name liraglutide product. The FDA database lists it as liraglutide in a solution for subcutaneous injection at a strength of 18 mg per 3 mL, or 6 mg/mL ^[1]. It is listed as a human prescription drug, with the manufacturer given as Lupin Pharmaceuticals, Inc. ^[1].

Two package configurations are listed, under the package codes 70748-346-02 and 70748-346-03, and the product's national drug code is 70748-346 ^[1]. The record lists an original application and a therapeutic equivalence code of AP1 ^[1].

The database classifies liraglutide as a GLP-1 receptor agonist ^[1]. That is the same broad drug class as semaglutide, sold as Ozempic, Wegovy and Rybelsus, and tirzepatide, sold as Mounjaro and Zepbound.

Why it matters for patients

For most patients, a generic approval matters through price, supply, and what a pharmacy actually has on the shelf. None of that appears in the approval record. The database entry does not list a launch date, a wholesale price, or a statement that the product is already shipping ^[1]. It also does not name the brand product it references in a way that describes the approved uses.

So it has not been reported when Lupin's liraglutide will reach pharmacies, what it will cost, or how insurance plans will cover it. Whether a specific product is in stock and what a patient pays for it are set by pharmacies and insurers, not by the approval record itself.

The record also does not say what device the product comes in, such as a pen or a vial-and-syringe format, or spell out the basis for the therapeutic equivalence code it lists ^[1]. Liraglutide is an injectable drug, and the approved strength listed is the same 6 mg/mL figure used by the brand ^[1].

What has not been reported

Several things a patient might want to know are absent from the approval record. Pricing, launch timing, supply, and whether Lupin has begun manufacturing have not been disclosed ^[1]. Whether other companies also hold approvals for generic liraglutide, or have applications pending, is not addressed in this record ^[1].

Also not stated in the database entry: whether the approval involves any patent litigation or settlement, and how many years of market protection the brand product may still hold ^[1].

What the record does establish is narrower. An application filed by Lupin under the abbreviated new drug application pathway — the route used for generic copies of already-approved drugs — was approved on July 22, 2025, for liraglutide injection ^[1]. The approval adds another FDA-cleared source of the drug in the United States, but the practical effect on price and access will depend on decisions that have not yet been made public.